Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Adherex Announces Completion of Patient Enrollment and Maintains TSX Listing Status

RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (Marketwire) -- 01/06/13 -- Adherex Technologies Inc. (TSX:AHX) (OTCQB:ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, is pleased to announce the following positive developments:


--  Completion of Patient Enrollment - The Company has completed patient
    enrollment in the Company's Phase 2 clinical trial for Metastatic Breast
    Cancer comparing the oral regimen of eniluracil + 5-fluorouracil (5-FU)
    and leucovorin (Treatment Arm 1) versus capecitabine
    (Xeloda®)(Treatment Arm 2). Patients who have disease progression in
    Arm 2 may crossover to take eniluracil plus 5-FU and leucovorin
    (Treatment Arm X). Enrollment in the study exceeded initial recruitment
    expectations. The Company expanded the initial enrollment target from
    140 patients to 153 patients and enrolled 21 patients in Arm X. Final
    efficacy and safety data is expected to be available during the second
    or third quarter of 2013. 

--  Adherex Maintains Listing Status - The Toronto Stock Exchange ("TSX")
    has lifted its review of the eligibility of the common shares of the
    Company for continued listing as the Company has demonstrated that it
    meets the continued listing requirements of the TSX. 

--  Updated Corporate Presentation - The Company would like to invite all
    interested parties to view the Company's updated corporate presentation
    at www.adherex.com under the Investors & Media section. 

Rosty Raykov, Chief Executive Officer of Adherex, said "We are pleased to have completed the enrollment phase of the trial within a reasonable time frame and wish to thank our CRO, contractors and employees whose efforts helped make this possible. We are also very pleased that the clinical investigator and patient communities have expressed strong support for eniluracil. We look forward to completing the treatment phase of the trial and releasing final efficacy and safety results later this year."

About Eniluracil

Eniluracil is a mechanism-based inactivator of DPD, the enzyme that rapidly breaks down 5-FU. Accordingly, Eniluracil increases the 5-FU elimination half-life from about 15 minutes to 5 hours and enables 5-FU to be administered orally, making it 100% orally bioavailable. In addition, Eniluracil prevents the formation of alpha-fluoro-beta-alanine (F-Bal), the 5-FU-breakdown product. F-Bal appears to cause hand-foot syndrome and neurotoxicity. It also decreases the antitumor activity of 5-FU in laboratory animals. Furthermore, because DPD is present in variable levels, the highly variable and nonlinear pharmacokinetics of 5-FU become predictable and linear when DPD is inactivated by Eniluracil in cancer patients.

The weekly regimen used in the current Phase 2 trial is based on a Phase 1 Eniluracil/5-FU/Leucovorin trial that produced durable tumor responses and no hand-foot syndrome in advanced colorectal cancer patients who were refractory to intravenous 5-FU/Leucovorin. In a similar Phase 2 study with capecitabine, no tumor responses occurred and 87% of the patients experienced hand-foot syndrome, a painful condition that may require dosing interruptions and dose reductions. The regimen was modified according to the methods described in the Adherex patent applications.

Except for historical information described in this press release, all other statements are forward-looking. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2011. Adherex Technologies, Inc. disclaims any obligation to update these forward-looking statements except as required by law.

For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.

Contacts:
Adherex Technologies Inc.
Rosty Raykov
Chief Executive Officer
(919) 636-5144

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
The notion of improving operational efficiency is conspicuously absent from the healthcare debate - neither Obamacare nor the newly proposed GOP plan discusses the impact that a step-function improvement in efficiency could have on access to healthcare (through more capacity), quality ...
In 2011, Marc Andreessen wrote a thought provoking article in the Wall Street Journal that software is eating the world. Today, in 2017, we can say that cloud transformation is happening all around us and cloud is now indeed eating the world. While Cloud services consumption is becomin...
Thanks to the plethora of communication and messaging apps available to the average user, unified communications (UC) is becoming more important than ever before. UC is a set of products and services designed to give employees a uniform communications experience, integrating different ...
Cloud providers like AWS have proven to be a viable option for running mainframe application workloads. The most effective method to exploit the value of Unisys mainframe applications and data is a transformative migration to modern systems frameworks in AWS, reusing as much of the ori...
Having a well-rounded brand strategy helps you identify the marketing channels you must focus on, and defines every aspect of how your business is viewed by your customers. Marketing and advertising is an integral component of every business. The US Small Business Administration reco...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE